Myositis-Related Interstitial Lung Disease: A Respiratory Physician's Point of View.
Yuko WasedaPublished in: Medicina (Kaunas, Lithuania) (2021)
Idiopathic inflammatory myositis (IIM) is an umbrella term for diseases of unknown origin that cause muscle inflammation. Dermatomyositis and polymyositis are IIMs that commonly cause interstitial lung disease (ILD). When a patient presents with ILD, the evaluation of whether the case displays the characteristics of myositis should be determined by interview, physical examination, imaging findings, the measurement of myositis-related antibodies, and the determination of disease severity after diagnosis. Rapidly progressing anti-melanoma differentiation-associated gene 5 antibody-positive ILD may require rapid multi-drug therapy, while anti-aminoacyl tRNA synthetase (ARS) antibody-positive ILD can be treated with anti-inflammatory drugs. Importantly, however, anti-ARS antibody-positive ILD often recurs and sometimes develops into fibrosis. Early diagnosis is crucial for treatment, and we therefore need to clarify the features of myositis associated with ILD and suspect these pathologies early. This section reviews what clinicians need to look for and what findings are evaluated in patients when diagnosing myositis associated with ILD.
Keyphrases
- interstitial lung disease
- systemic sclerosis
- rheumatoid arthritis
- idiopathic pulmonary fibrosis
- oxidative stress
- end stage renal disease
- newly diagnosed
- ejection fraction
- primary care
- chronic kidney disease
- anti inflammatory drugs
- emergency department
- preterm infants
- mental health
- high resolution
- prognostic factors
- genome wide
- gene expression
- systematic review
- stem cells
- physical activity
- peritoneal dialysis
- disease activity
- randomized controlled trial
- dna methylation
- photodynamic therapy
- replacement therapy
- preterm birth
- solid phase extraction
- patient reported
- respiratory tract
- smoking cessation